相关临床试验
109
41 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1948
进行中（未招募）
20
18.4%
已完成
43
39.5%
尚未招募
21
19.3%
招募中
18
16.5%
暂停
3
2.8%
终止
3
2.8%
Unknown
1
0.9%
暂无批准数据
- The UK will become the first country to roll out CSL Seqirus' adjuvanted trivalent influenza vaccine Aujemflu, ahead of the 2027/28 flu season under a government agreement. - Aujemflu, approved by the MHRA in June for people aged 50 and over, combines the MF59 adjuvant, cell-based manufacturing and a higher-dose formulation. - The NHS will use it for adults aged 65 and over and at-risk adults aged 50 to 64, and the deal extends pandemic flu vaccine supply through 2031.
- India's Central government approved the Biovigilance Programme of India, led by the Indian Pharmacopoeia Commission, to monitor adverse events tied to transplant medicines and biological products. - The programme covers products given to both organ and tissue donors and recipients, complementing existing pharmacovigilance and materiovigilance monitoring efforts. - Officials also launched the 7th Edition of the National Formulary of India, the ADR-PvPI 2.0 mobile app for iOS, and hospital guidance on medical device adverse events. - India has risen from 123rd place in 2009-2014 to 8th globally in contributions to the WHO patient safety database, with about 1,150 ADR reporting centres operating.
- Takeda Biopharmaceuticals India and Dr Reddy's Laboratories have entered a distribution agreement covering QDENGA, India's first approved dengue vaccine, in the country's private market. - Dr Reddy's will exclusively promote and distribute QDENGA for paediatric and adult vaccination, with availability anticipated in the first half of 2027 pending local authority processes. - The deal follows CDSCO marketing authorisation in July 2026 for individuals aged 4 to 60 years, and Takeda retains public-market rights plus medical and brand oversight. - Dengue cases in India have risen 11-fold over two decades, and a nationwide ICMR surveillance study found all four serotypes co-circulating, with 1 in 14 patients infected with multiple serotypes.
- WHO and Global Platform partners launched a 2026-2030 market shaping strategy to fix fragile supply of essential childhood cancer medicines in low- and middle-income countries. - A baseline assessment of 51 hospitals in 12 countries found only about 45% of essential childhood cancer medicines were available. - WHO issued its first prequalification invitation covering six established medicines: pegaspargase, asparaginase, hydrocortisone, dactinomycin, vincristine and cytarabine. - The strategy sets out ten interlinked interventions including pooled procurement, volume guarantees and voluntary licensing for newer therapies.
- NanoViricides' Phase IIA/IIB trial of oral NV-387 gummies for Bundibugyo Ebolavirus is set to start next week at an Ebola treatment center in Ituri province, DRC. - The adaptive trial adds an oral option to the WHO-linked PARTNERS study, which is evaluating infused MBP134 and remdesivir in roughly 300 enrolled patients. - As of September 10, 2026, DRC has reported 7,022 confirmed cases, 3,398 confirmed deaths and 1,671 recoveries, with a crude fatality rate near 48%.
- The World Health Organization has opened a public consultation on improving the inclusion of underrepresented populations in clinical trials, running from 14 September to 29 October 2026. - The consultation seeks views on current challenges, barriers to participation, priorities for improving inclusion and actions to strengthen trial design, recruitment, reporting, accountability and community engagement. - Findings will feed into recommendations developed under a WHO-supported international project led by Cochrane Response, with consultation activities led by researchers at La Trobe University.
- Gilead Sciences and the Pan American Health Organization signed an agreement to accelerate access to twice-yearly lenacapavir for HIV pre-exposure prophylaxis across all PAHO Member States. - The deal uses PAHO's Regional Revolving Funds to create a coordinated regional procurement pathway, adding 14 countries outside Gilead's existing voluntary licensing agreements. - PAHO estimates roughly 140,000 new HIV infections occur annually in Latin America and the Caribbean, where new infections rose 13% between 2010 and 2024. - Lenacapavir is a first-in-class HIV capsid inhibitor with a multi-stage mechanism of action and no known in-vitro cross-resistance to existing antiretroviral classes.
- Bayer's Monsanto unit appeared before a Missouri state court seeking final approval of a $7.25 billion settlement covering roughly 65,000 Roundup claims alleging non-Hodgkin lymphoma. - Judge Timothy Boyer of the Missouri Circuit Court in St. Louis heard objections from plaintiffs' attorneys who argue the deal blocks claimants from taking their cases to trial. - The settlement follows a June Supreme Court ruling that FIFRA preempts state failure-to-warn claims where the EPA has confirmed product safety. - Bayer's pharmaceutical arm meanwhile secured FDA approvals for sevabertinib in lung cancer and an expanded Kerendia indication in chronic kidney disease with type 1 diabetes.
- WHO granted prequalification to a three-dose vial presentation of Pfizer's maternal RSV vaccine Abrysvo, enabling large-scale distribution in lower-income countries. - RSV is the second leading cause of infant mortality globally after malaria, with over 100,000 deaths annually in children under five and more than 97% in low- and middle-income countries. - Pivotal Phase 3 trials showed 81.8% efficacy against severe RSV-associated lower respiratory disease in infants' first 90 days, sustained at 69.4% through six months.
- Egypt's drug regulator secured WHO prequalification for its pharmaceutical quality control laboratories, the first Egyptian regulatory labs to earn the designation. - The EDA already holds WHO Maturity Level 3 for both medicines and vaccines, making Egypt the first African country to reach that milestone in both fields. - Prime Minister Mostafa Madbouly met EDA Chairman Ali El-Ghamrawy to review progress toward WHO Maturity Level 4 accreditation. - Officials say the recognition should boost confidence in Egyptian-made medicines and ease their access to global markets.
